<DOC>
	<DOCNO>NCT03038035</DOCNO>
	<brief_summary>MLC601 ( Neuroaid ) Traditional Chinese Medicine ( TCM ) neuroprotective neuroproliferative property cellular animal model brain injury . It contain 9 herbal 5 non-herbal component . MLC901 ( Neuroaid II ) , simplify formula MLC601 , contain 9 herbal component yet show efficacy become available . This study carry find NEUROAID II ( MLC901 ) safe take together establish medicine Alzheimer 's disease whether NEUROAID II ( MLC901 ) help slow Alzheimer 's disease progression . This study 6-month randomize , double-blind , placebo-controlled trial , follow open extension study subject complete main 6 month trial ( irrespective treatment allocation ) offer open-labelled MLC901 another 6 month .</brief_summary>
	<brief_title>The Alzheimer 's Disease THErapy With NEuroaid ( ATHENE ) Study</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cholinesterase Inhibitors</mesh_term>
	<criteria>Male female , age â‰¥50 year Diagnosed probable AD accord NINCDSADRDA criterion , MMSE score 10 24 , Receiving AChEI Memantine past 6 month prior screen stable dose past 4 month ( stable dose define 5 10mg/day Donepezil , 3 , 4.5 6 mg twice daily rivastigmine capsule , 4.6 9.5 mg rivastigmine transdermal patch daily , 8 12 mg twice daily galantamine tablet , 16 24 mg daily galantamine capsule XL , 10 mg OD 10 mg BD Memantine ) Patient legal representative able provide inform consent Patients receive investigational product within 60 day 5 halflives prior screen Any serious medical psychiatric condition investigator 's judgement may jeopardize patient his/her participation study may hamper his/her ability perform complete procedure require study .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>